Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
38237
CAS Number:
162401-32-3
Roflumilast
Purity:
≥ 98 % (HPLC)
Synonym(s):
3-(cyclopropylméthoxy)- N -(3,5-dichloropyridin-4-yl)-4-(difluorométhoxy)benzamide, 3-cyclopropylméthoxy-4-difluorométhoxy- N -[3,5-dichloropyrid-4-yl]-benzamide
Documents
$168.35 /250 mg
Taille
Request Bulk Quote
Informations sur le produit

Roflumilast is a potent phosphodiesterase-4 (PDE4) inhibitor, primarily utilized in the management of chronic obstructive pulmonary disease (COPD). This compound works by reducing inflammation in the airways, thereby improving lung function and overall respiratory health. Its unique mechanism of action makes it particularly beneficial for patients who experience frequent exacerbations, offering a targeted approach to long-term management. Roflumilast is also being explored for potential applications in other inflammatory conditions, showcasing its versatility in therapeutic use.

In research settings, Roflumilast serves as a valuable tool for studying the pathways involved in inflammation and respiratory diseases. Its ability to modulate immune responses positions it as a promising candidate for further investigation in various therapeutic areas. With a favorable safety profile and the potential to enhance the efficacy of other treatments, Roflumilast stands out as a significant advancement in respiratory medicine.

Numéro CAS 
162401-32-3
Formule moléculaire
C17H14Cl2F2N2O3
Poids moléculaire 
403.21
Point de fusion 
157 - 161 °C
Informations générales
Numéro CAS 
162401-32-3
Formule moléculaire
C17H14Cl2F2N2O3
Poids moléculaire 
403.21
Point de fusion 
157 - 161 °C
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Roflumilast is widely utilized in research focused on

  • Chronic Obstructive Pulmonary Disease (COPD) Treatment: It is primarily used as a treatment for COPD, helping to reduce inflammation and improve lung function, which is crucial for patients managing this chronic condition.
  • Anti-inflammatory Research: Researchers explore its anti-inflammatory properties, making it valuable in studies aimed at understanding and developing treatments for various inflammatory diseases.
  • Pharmaceutical Development: The compound serves as a model for developing new medications, particularly in the respiratory field, due to its unique mechanism of action as a phosphodiesterase-4 inhibitor.
  • Combination Therapy Studies: It is often investigated in combination with other drugs to enhance therapeutic effects in respiratory diseases, providing insights into more effective treatment regimens.
  • Clinical Trials: Roflumilast is a key subject in clinical trials aimed at assessing its efficacy and safety, contributing to the advancement of respiratory health treatments.

Citations